Abstract
Previous reports from the PANDA III trial had proven that the BuMA (SinoMed, Tianjin, China) biodegradable polymer (BP) sirolimus-eluting stents (SES), with faster drug eluting rate and polymer absorption kinetics, was non-inferior to the Excel (JW Medical, Weihai, China) SES in an all-comer
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.